Fukui T, Mamesaya N, Takahashi T, Kishi K, et al. A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040). J Thorac Oncol 2025 Jan 2:S1556-0864(24)02548.
PMID: 39755169